Editor's Choice
Pharma & Human Health
Editor's Choice
Did you miss Probiota Copenhagen 2022? Catch up now!
With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]
Finance
Microba Life Sciences Completes Successful IPO & Announces Partnership with Ginkgo Bioworks
Microba Life Sciences (ASX:MAP), a precision microbiome science company, commenced trading on the Australian Securities Exchange (ASX) on April 4th following the completion of an initial public offering (IPO). The IPO raised $30.0 million and […]
Finance
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a […]
Pharma & Human Health
Researchers identify potential approaches to modify the vaginal microbiome
The female genital tract is naturally colonized by mixed communities of bacteria, known as the vaginal microbiome. When these communities are dominated by species such as Lactobacillus crispatus, they provide important protective functions in genital health. […]
Finance
How insights from the field of advanced therapy medicinal products (ATMPs) can inform solutions in the microbiome field
Upcoming panel at Pharmabiotics Conference & Partnering 2022 will explore what microbiome drug developers can learn from another area of pharmaceutical innovation Live Biotherapeutic Products (LBPs) emerging from microbiome-related scientific innovation are novel and exciting […]
Pharma & Human Health
A new photoactive viral vector for anti-cancer therapy has been developed
A research team at the University of Bologna has developed a new targeted cancer therapy based on the action of a genetically modified phage, a virus that infects bacteria. The study made the cover of […]
Finance
Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, and BIOASTER, the first Institute for Technological Innovation in Microbiology, announce the implementation of research collaboration to use […]
Pharma & Human Health
Deciphering gut microbiome ‘chatter’ to combat IBD
Scientists at the Earlham Institute, Quadram Institute and University of East Anglia on the Norwich Research Park, have developed a new computational biology method to better understand IBD for targeted clinical treatments. By analysing specific […]
Finance
SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark
SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern […]
Finance
Microbiotica raises $67M to advance pipeline of microbiome-based therapeutics
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. […]